Form 8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of

the Securities Exchange Act of 1934

 

September 26, 2005

Date of Report (date of earliest event reported)

 

 

HEMOSENSE, INC.

(Exact name of Registrant as specified in its charter)

 

 

Delaware   001-32541   77-0452938

(State or other jurisdiction of

incorporation or organization)

   (Commission File Number)  

(I.R.S. Employer

Identification Number)

 

651 River Oaks Parkway

San Jose, California 95134

(Address of principal executive offices)

 

(408) 719-1393

(Registrant’s telephone number, including area code)

 

N/A

(Former name or former address, if changed since last report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Item 5.02. Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers.

 

On September 26, 2005, Richard P. Powers was appointed to the Company’s Board of Directors as a new sixth member of the Board. Mr. Powers will serve as a Class III director on the Board. Mr. Powers also has been appointed to the Company’s Audit Committee, replacing Greg Ayers, who remains on the Board. Mr. Powers will also serve as chairman of the Audit Committee. The Company is issuing a press release regarding the appointment of Mr. Powers to the Company’s Board of Directors. A copy of the press release is furnished as Exhibit 99.1 to this Form 8-K.

 

This information shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

 

Item 9.01. Financial Statements and Exhibits.

 

  (c) Exhibits.

 

Exhibit No.
  

Description

99.1   Press Release of HemoSense, Inc. dated as of September 29, 2005.

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

    HEMOSENSE, INC.
Date: September 29, 2005   By:  

/s/ James D. Merselis

        James D. Merselis
        President and Chief Executive Officer